1. Home
  2. FBIO vs GANX Comparison

FBIO vs GANX Comparison

Compare FBIO & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FBIO
  • GANX
  • Stock Information
  • Founded
  • FBIO 2006
  • GANX 2017
  • Country
  • FBIO United States
  • GANX United States
  • Employees
  • FBIO N/A
  • GANX N/A
  • Industry
  • FBIO Biotechnology: Pharmaceutical Preparations
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FBIO Health Care
  • GANX Health Care
  • Exchange
  • FBIO Nasdaq
  • GANX Nasdaq
  • Market Cap
  • FBIO 39.4M
  • GANX 41.9M
  • IPO Year
  • FBIO N/A
  • GANX 2021
  • Fundamental
  • Price
  • FBIO $1.83
  • GANX $1.64
  • Analyst Decision
  • FBIO Strong Buy
  • GANX Strong Buy
  • Analyst Count
  • FBIO 3
  • GANX 5
  • Target Price
  • FBIO $18.00
  • GANX $7.60
  • AVG Volume (30 Days)
  • FBIO 691.0K
  • GANX 203.8K
  • Earning Date
  • FBIO 11-14-2024
  • GANX 11-14-2024
  • Dividend Yield
  • FBIO N/A
  • GANX N/A
  • EPS Growth
  • FBIO N/A
  • GANX N/A
  • EPS
  • FBIO N/A
  • GANX N/A
  • Revenue
  • FBIO $81,501,000.00
  • GANX N/A
  • Revenue This Year
  • FBIO N/A
  • GANX N/A
  • Revenue Next Year
  • FBIO $134.70
  • GANX N/A
  • P/E Ratio
  • FBIO N/A
  • GANX N/A
  • Revenue Growth
  • FBIO 31.51
  • GANX N/A
  • 52 Week Low
  • FBIO $1.36
  • GANX $0.89
  • 52 Week High
  • FBIO $4.43
  • GANX $5.33
  • Technical
  • Relative Strength Index (RSI)
  • FBIO 49.60
  • GANX 42.64
  • Support Level
  • FBIO $1.78
  • GANX $1.59
  • Resistance Level
  • FBIO $2.27
  • GANX $1.70
  • Average True Range (ATR)
  • FBIO 0.17
  • GANX 0.15
  • MACD
  • FBIO -0.03
  • GANX 0.00
  • Stochastic Oscillator
  • FBIO 21.43
  • GANX 19.74

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: